Management of vitiligo. Results of a questionnaire among dermatologists in the Netherlands

International Journal of Dermatology

Volumn 38, Issue 11, 1999, Pages 866-872

  Njoo, M David ^a,b   Bossuyt, Patrick M M ^a   Westerhof, Wiete ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PSORALEN;

CONFERENCE PAPER; CORTICOSTEROID THERAPY; DRUG INDICATION; HUMAN; NETHERLANDS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DERMATOLOGY; GLUCOCORTICOIDS; HUMANS; NETHERLANDS; PATIENT EDUCATION; PHYSICIAN'S PRACTICE PATTERNS; PUVA THERAPY; QUESTIONNAIRES; SKIN TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME; VITILIGO;

EID: 0032713199     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00822.x     Document Type: Conference Paper

References (25)

1. Mosher DB, Fitzpatrick TB, Ortonne JP. Disorders of pigmentation: vitiligo. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. New York: McGraw-Hill, 1993: 903-995.
2. Porter JR, Mawr B, Hill-Beuf A, et al. Response to cosmetic disfigurement: patients with vitiligo. Cutis 1987; 39: 493-494.
3. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol 1996; 35: 620-626.
4. Woolf SH. Practice guidelines: a new reality in medicine. II. Methods of developing guidelines. Arch Intern Med 1992; 152: 946-952.
5. Ladhani S. The need for evidence based management of skin diseases. Int J Dermatol 1997; 36: 17-22.
6. Westerhof W, Bolhaar B, Menke HE, Harper JI. Resultaten van een enquête onder vitiligo patienten. Ned Tijdschr Dermatol Venereol 1996; 6: 100-105.
7. Hann SK, Chun WH, Park YK. Clinical characteristics of progressive vitiligo. Int J Dermatol 1997; 36: 353-355.
8. Chun WH, Hann SK. The progression of non-segmental vitiligo: clinical analysis of 318 patients. Int J Dermatol 1997; 36: 908-910.
9. Pathak MA, Mosher DB, Fitzpatrick TB. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5,8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr 1984; 66: 165-173.
10. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997; 15: 921-926.
11. Köster W, Wiskemann A. Phototherapy with UV-B in vitiligo. Zeitschr Hautkrank 1990; 65: 1022-1024.
12. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with narrowband UV-B versus topical psoralen plus UV-A. Arch Dermatol 1997; 133: 1525-1528.
13. Stern R, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-1585.
14. Buckley DA, Rogers S. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol 1996; 21: 43-45.
15. Takeda H, Mitsuhashi Y, Kondo S. Multiple squamous cell carcinomas in situ in vitiligo after long-term PUVA therapy. J Am Acad Dermatol 1998; 38: 268-270.
16. Westerhof W, Schallreuter KU. PUVA for vitiligo and skin cancer. Clin Exp Dermatol 1996; 22: 54.
17. Studniberg HM, Weller P. PUVA, UVB, psoriasis and non-melanoma skin cancer. J Am Acad Dermatol 1993; 29: 1013-1022.
18. Kenney JA, Jr. Vitiligo treated by psoralens. A long-term follow-up study of the permanency of repigmentation. Arch Dermatol 1971; 103: 475-480.
19. Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electron microscopic studies. Br J Dermatol 1976; 94 (Suppl. 12): 43-50.
20. Kumari J. Vitiligo treated with topical clobetasolpropionate. Arch Dermatol 1984; 120: 631-635.
21. Xunquan L, Changgeng S, Peiying J, et al. Treatment of localized vitiligo with Ulobetasol cream. Int J Dermatol 1990; 29: 295-297.
22. Westerhof W, Nieuweboer-Krobotova L, Mulder PGH, Glazenburg EJ. Left-right comparison study of the combination fluticasone propionate and UVA vs. either fluticasone propionate or UVA alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135: 1061-1066.
23. Eddy DM. Practice policies: guidelines for methods. JAMA 1990; 263: 1839-1841.
24. Eddy DM. Designing a practice policy. Standards, guidelines and options. JAMA 1990; 263: 3077-3084.
25. Sackett DL, Rosenberg WM, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. Br Med J 1996; 312: 71-72.